Skip to main content
Book cover

Congestive Heart Failure

Proceedings of the Symposium on New Drugs and Devices October 30–31, 1986, Philadelphia, Pennsylvania

  • Conference proceedings
  • © 1987

Overview

Part of the book series: Developments in Cardiovascular Medicine (DICM, volume 75)

This is a preview of subscription content, log in via an institution to check access.

Access this book

eBook USD 189.00
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book USD 249.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book USD 249.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Other ways to access

Licence this eBook for your library

Institutional subscriptions

Table of contents (19 papers)

  1. Preclinical Issues and Proarrhythmia Definitions

  2. Therapeutic Strategies

Keywords

About this book

About 2. 5 million individuals have congestive heart fai lure in the United States with over 400,000 new cases expected annually. Congestive heart failure also is one of the commonest causes for hospital admissions accounting for over 5 million hospital days per year. Despite the early recognition of this condition and active medical research into both mechanisms and therapy, prognosis continues to remain dismal wi th less than a 50% expected five year survival. In the last decade we have seen many new medical and therapeutic options for patients with congestive heart failure which extend beyond the use of bed rest, sodium restriction, digitalis and diuretics. These include vasodilators of a variety of types including the angiotensin conventional enzyme (ACE) inhibitors. Also, many new inotropes are under active investigation both in oral and intravenous forms. In March of 1984 a survey of over 5000 physicians was performed under the auspices of the American Heart Association (reported in: JAOC 8:966, 1986). That survey showed that there was no universally accepted defini tion for congestive heart fai lure and that a wide spectrum of diagnostic cri teria for this common condi tion existed even among academic cardiologists. There was no clear standard as to even the mos t bas ic treatment of conges t i ve heart fai lure. For example, exercise restriction was recommended by 19% of physicians, 31% recommended no change in activity, and 50% either light exercise or an exercise conditioning program.

Editors and Affiliations

  • Likoff Cardiovascular Institute, Hahnemann University, Philadelphia, USA

    Joel Morganroth

  • School of Veterinary Medicine, University of Pennsylvania, Philadelphia, USA

    E. Neil Moore

Bibliographic Information

  • Book Title: Congestive Heart Failure

  • Book Subtitle: Proceedings of the Symposium on New Drugs and Devices October 30–31, 1986, Philadelphia, Pennsylvania

  • Editors: Joel Morganroth, E. Neil Moore

  • Series Title: Developments in Cardiovascular Medicine

  • DOI: https://doi.org/10.1007/978-1-4613-2077-7

  • Publisher: Springer New York, NY

  • eBook Packages: Springer Book Archive

  • Copyright Information: Martinus Nijhoff Publishing, Boston 1987

  • Hardcover ISBN: 978-0-89838-955-5Published: 31 October 1987

  • Softcover ISBN: 978-1-4612-9232-6Published: 22 September 2011

  • eBook ISBN: 978-1-4613-2077-7Published: 06 December 2012

  • Series ISSN: 0166-9842

  • Edition Number: 1

  • Number of Pages: XIV, 290

  • Topics: Cardiology

Publish with us